INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8101, 19630, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8102, 22672, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8103, 22676, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8104, 22677, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8105, 22679, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8106, 22680, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8107, 26297, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8108, 28488, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8109, 28489, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8110, 28490, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8111, 28491, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8112, 28492, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8113, 30008, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8114, 30543, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8115, 33203, 'Metronidazole', 'Diseases requiring dialysis', 'Metronidazole and its metabolites are moderately removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8116, 690, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8117, 691, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8118, 692, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8119, 4210, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8120, 4325, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8121, 4894, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8122, 4903, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8123, 4904, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8124, 4905, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8125, 4906, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8126, 4930, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8127, 6077, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8128, 8101, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8129, 8102, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8130, 14075, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8131, 14076, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8132, 14080, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8133, 15559, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8134, 16787, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8135, 17956, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8136, 17957, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8137, 18347, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8138, 19075, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8139, 19077, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8140, 19078, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8141, 19079, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8142, 19085, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8143, 19630, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8144, 22672, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8145, 22676, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8146, 22677, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8147, 22679, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8148, 22680, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8149, 26297, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8150, 28488, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8151, 28489, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8152, 28490, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8153, 28491, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8154, 28492, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8155, 30008, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8156, 30543, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8157, 33203, 'Metronidazole', 'Liver Diseases', 'Metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with metronidazole should be administered cautiously at reduced dosages in patients with severe liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8158, 690, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8159, 691, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8160, 692, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8161, 4210, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8162, 4325, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8163, 4894, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8164, 4903, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8165, 4904, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8166, 4905, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8167, 4906, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8168, 4930, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8169, 6077, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8170, 8101, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8171, 8102, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8172, 14075, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8173, 14076, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8174, 14080, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8175, 15559, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8176, 16787, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8177, 17956, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8178, 17957, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8179, 18347, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8180, 19075, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8181, 19077, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8182, 19078, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8183, 19079, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8184, 19085, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8185, 19630, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8186, 22672, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8187, 22676, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8188, 22677, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8189, 22679, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8190, 22680, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8191, 26297, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8192, 28488, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8193, 28489, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8194, 28490, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8195, 28491, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8196, 28492, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8197, 30008, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8198, 30543, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8199, 33203, 'Metronidazole', 'Heart Failure', 'Flagyl I.V. RTU (brand of metronidazole ready-to-use injection) contains 14 mEq of sodium per each 500 mg dose of metronidazole.  The sodium content should be considered when this product is used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8200, 690, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
